152 related articles for article (PubMed ID: 22233823)
1. Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.
Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Matsuura Y; Tamiya M; Morishita N; Higashiguchi M; Tsumori T; Kawase I
J Chemother; 2011 Dec; 23(6):367-70. PubMed ID: 22233823
[TBL] [Abstract][Full Text] [Related]
2. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
Enomoto Y; Inui N; Imokawa S; Karayama M; Hasegawa H; Ozawa Y; Matsui T; Yokomura K; Suda T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):499-505. PubMed ID: 26134440
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
[TBL] [Abstract][Full Text] [Related]
5. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
[TBL] [Abstract][Full Text] [Related]
6. [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department].
Hureaux J; Alizon C; Urban T
Rev Mal Respir; 2012 May; 29(5):680-7. PubMed ID: 22682594
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan.
Tiseo M; Buti S; Boni L; Mattioni R; Ardizzoni A
Lung Cancer; 2014 Oct; 86(1):91-5. PubMed ID: 25130081
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
[TBL] [Abstract][Full Text] [Related]
9. Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
Fujimoto D; Shimizu R; Kato R; Sato Y; Kogo M; Ito J; Teraoka S; Otoshi T; Nagata K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Anticancer Res; 2015 Nov; 35(11):6261-6. PubMed ID: 26504060
[TBL] [Abstract][Full Text] [Related]
10. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
12. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
Garst J; Buller R; Lane S; Crawford J
Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
[TBL] [Abstract][Full Text] [Related]
13. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Wakuda K; Kenmotsu H; Naito T; Akamatsu H; Ono A; Shukuya T; Nakamura Y; Tsuya A; Murakami H; Takahashi T; Endo M; Nakajima T; Yamamoto N
Am J Clin Oncol; 2015 Feb; 38(1):28-32. PubMed ID: 23388567
[TBL] [Abstract][Full Text] [Related]
17. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
18. Severe interstitial lung disease associated with amrubicin treatment.
Yoh K; Kenmotsu H; Yamaguchi Y; Kubota K; Ohmatsu H; Goto K; Niho S; Ohe Y; Saijo N; Nishiwaki Y
J Thorac Oncol; 2010 Sep; 5(9):1435-8. PubMed ID: 20683210
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
20. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
